Guidelines for the diagnosis and management of aplastic anaemia.
about
First-line allogeneic hematopoietic stem cell transplantation of HLA-matched sibling donors compared with first-line ciclosporin and/or antithymocyte or antilymphocyte globulin for acquired severe aplastic anemiaHow I treat acquired aplastic anemiaPathophysiology and management of thrombocytopenia in bone marrow failure: possible clinical applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromesAplastic anemia in adolescents and young adultsManagement of neutropenic patients in the intensive care unit (NEWBORNS EXCLUDED) recommendations from an expert panel from the French Intensive Care Society (SRLF) with the French Group for Pediatric Intensive Care Emergencies (GFRUP), the French SEltrombopag for the treatment of aplastic anemia: current perspectivesClonal hematopoiesis in acquired aplastic anemiaChild with aplastic anemia: Anesthetic management.Dysplasia features of myelodysplastic syndrome in ethnically Chinese people.Immature platelet fraction levels in a variety of bone marrow pathologies in South African HIV-positive patients with thrombocytopenia.Challenges of caring for an advanced chronic kidney disease patient with severe thrombocytopenia.Proposal of criteria for dyserythropoiesis in the diagnosis of myelodysplastic syndromes.Hypomegakaryocytic thrombocytopenia (HMT): an immune-mediated bone marrow failure characterized by an increased number of PNH-phenotype cells and high plasma thrombopoietin levels.Left main crossover stenting in a patient with severe thrombocytopenia due to aplastic anemia.Epstein-Barr Virus-associated Lymphoproliferative Disorder with Encephalitis Following Anti-thymocyte Globulin for Aplastic Anemia Resolved with Rituximab Therapy: A Case Report and Literature ReviewProlonged cyclosporine administration after antithymocyte globulin delays but does not prevent relapse in severe aplastic anemia.Bone marrow mesenchymal stem cells from patients with aplastic anemia maintain functional and immune properties and do not contribute to the pathogenesis of the disease.First-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia.Allogeneic hematopoietic stem cell transplantation as the first-line treatment option in a patient with severe aplastic anemia without a matched related donor: A case report.Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow TransplantationSTAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donorsRecent advances in treatment of aplastic anemia.Increased bone marrow (BM) plasma level of soluble CD30 and correlations with BM plasma level of interferon (IFN)-γ, CD4/CD8 T-cell ratio and disease severity in aplastic anemiaIncidence and clinical characteristics of clonal cytogenetic abnormalities of acquired aplastic anemia in adultsOptimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials NeFirst-line treatment for severe aplastic anemia in children: bone marrow transplantation from a matched family donor versus immunosuppressive therapyIFN-γ causes aplastic anemia by altering hematopoietic stem/progenitor cell composition and disrupting lineage differentiation.Diagnosis and treatment of pediatric acquired aplastic anemia (AAA): an initial survey of the North American Pediatric Aplastic Anemia Consortium (NAPAAC)Iron-chelating therapy for transfusional iron overloadNatural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemiaSNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes.Granulocyte transfusion combined with granulocyte colony stimulating factor in severe infection patients with severe aplastic anemia: a single center experience from China.Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia.Safety and efficacy of indigenous equine antithymocyte globulin along with cyclosporine in subjects with acquired aplastic anemia.Recombinant human thrombopoietin treatment promotes hematopoiesis recovery in patients with severe aplastic anemia receiving immunosuppressive therapy.Somatic mutations identify a subgroup of aplastic anemia patients who progress to myelodysplastic syndrome.Pediatric aplastic anemia and refractory cytopenia: A retrospective analysis assessing outcomes and histomorphologic predictors.Aplastic anemia and severe pancytopenia during treatment with peg-interferon, ribavirin and telaprevir for chronic hepatitis CAbnormal immunomodulatory ability on memory T cells in humans with severe aplastic anemia.
P2860
Q24201108-5DE87812-2C0D-408D-ACFF-D0512F6DAB24Q24617687-597FC8AA-A944-4923-8F5F-E70DA7D3CA08Q26863182-FD3119E1-8E9A-45E9-BA71-1A7E3A6E37DEQ26864775-2D25A2E2-7509-423A-9AD7-0CF268F05BBCQ27320711-F290322E-DD3C-4ADD-BF36-15A5A9F62DB0Q28071710-16506DCC-8068-41D7-8036-2081B724AAAFQ28079733-6848B41A-A8FE-4320-989E-37568044D96CQ33404444-0C58DE94-B9DE-499E-A0CD-33AFA6160C7EQ33411124-4C01D68A-D1DB-4CF1-909A-2B2B7CEB8A6BQ33411812-2ACB7F6A-930D-41B3-93EF-CFA713320569Q33412020-E00A76E5-903A-4643-B86C-C5D1DC1641BFQ33427880-F0F84B79-0969-4D42-B649-39EA27A2F92CQ33433460-A9E3A6CE-8844-40BB-8AF2-AE1FAA307414Q33437084-86C64985-0CAD-408F-B898-2DE8884A14B2Q33619215-EE7AF34A-1BA9-41EE-A8C4-FF587711E3C2Q33820120-B507BCF3-799D-4210-8183-32060466F78FQ33828556-F13AAC90-3A60-430A-B1DD-4D71520A88AFQ33889151-881E9899-21A6-4747-A268-1F42A38A0116Q34141361-2986C4CC-9EDD-4B82-A161-003C3DD0B3C2Q34272519-3F2EE1AF-4B29-4AE8-8A6F-46267CCC9793Q34362636-3922E38C-B92C-4D2A-9984-CC7738A48EC3Q34371142-9C6AD462-3A0D-44C9-BE8B-FA180540B69AQ34451351-9EFEAF0E-3F02-49D8-B2A9-E18205924A4EQ34482699-BF705EAD-56B6-41B7-9023-C3CF8A52DE2EQ34501072-E7976E2B-3C2E-44D5-A3CE-8E22E6975AA6Q34645147-7F61E7EE-A9FD-4531-BFF8-B33FAEC438B4Q34649082-EAA15F79-803B-4DB2-9E3C-C935DAB27636Q34683972-64084718-1315-4291-91E7-9CA26AAC4DA1Q34790303-D76E5A36-9534-44F2-869F-791FDB9D0417Q34806460-BF3960B7-EE23-43FD-AB58-44DC9A9E6EF8Q35061800-D41E09DD-ED78-4C29-BE4D-DF7A2353E1BDQ35083258-CAD1422F-6D13-493C-8459-EF35063EF1EAQ35088529-F3A2186F-691B-4EB3-AE28-BC9319D673B7Q35197402-E235945D-BC2F-4CB6-94D1-5BBAC930486EQ35220764-F78FDFA0-66E3-4557-BAE6-8EAF8B765AF2Q35226647-FE31A79F-3507-4D8E-85D7-440FE5C17725Q35252614-6F1A4BAC-A859-4391-80F7-D4EEE2033448Q35258960-1A779BD8-5C1D-4807-A0DE-7F43801C9DC6Q35567714-59EA05E4-899E-4C61-8958-62450FE9F8EAQ35740966-7EAE9A73-34EA-49EC-B9E9-5567CE7B9F90
P2860
Guidelines for the diagnosis and management of aplastic anaemia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Guidelines for the diagnosis and management of aplastic anaemia.
@en
Guidelines for the diagnosis and management of aplastic anaemia.
@nl
type
label
Guidelines for the diagnosis and management of aplastic anaemia.
@en
Guidelines for the diagnosis and management of aplastic anaemia.
@nl
prefLabel
Guidelines for the diagnosis and management of aplastic anaemia.
@en
Guidelines for the diagnosis and management of aplastic anaemia.
@nl
P2093
P2860
P1476
Guidelines for the diagnosis and management of aplastic anaemia.
@en
P2093
Andrew Laurie
Anna Martin
Edward C Gordon-Smith
Inderjeet Dokal
Jamie Cavenagh
Jane Keidan
Jane Mercieca
John A L Yin
Judith C W Marsh
Phil Darbyshire
P2860
P356
10.1111/J.1365-2141.2009.07842.X
P407
P577
2009-08-10T00:00:00Z